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Abstract Muscarinic acetylcholine receptor (mAChR)
activation of pancreatic b-cells elevates intracellular Ca2?
and potentiates glucose-stimulated insulin secretion. In
addition, it activates a number of signaling molecules,
including ERK1/2, whose activation has been shown to play
an important role in regulating pancreatic b-cell function and
mass. The aim of this work was to determine how mAChR
activation elevates intracellular Ca2? concentration ([Ca2?]i)
and activates ERK1/2 in the pancreatic b-cell line MIN6. We
demonstrate that agonist-stimulated ERK1/2 activation is
dependent on the activation of phospholipase C and an ele-
vation in [Ca2?]i, but is independent of the activation of
diacylglycerol-dependent protein kinase C isoenzymes.
Using a pharmacological approach, we provide evidence that
agonist-induced increases in [Ca2?]i and ERK activity
require (1) IP3 receptor-mediated mobilization of Ca
2? from
the endoplasmic reticulum, (2) influx of extracellular Ca2?
through store-operated channels, (3) closure of KATP chan-
nels, and (4) Ca2? entry via L-type voltage-operated Ca2?
channels. Moreover, this Ca2?-dependent activation of ERK
is mediated via both Ras-dependent and Ras-independent
mechanisms. In summary, this study provides important
insights into the multifactorial signaling mechanisms linking
mAChR activation to increases in [Ca2?]i and ERK activity.
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Introduction
Acetycholine (ACh) is released by intra-pancreatic vagal
nerve endings and activates muscarinic acetylcholine
receptors (mAChRs) on pancreatic b-cells during both the
pre-absorptive (cephalic phase) and absorptive phases of
nutrient intake [1–3]. mAChR activation in the pre-absorp-
tive and absorptive phase potentiates subsequent insulin
secretion [1, 2], and these different phases can be modulated
independently of each other in both the diabetic and non-
diabetic state [4]. Although multiple mAChR subtypes have
been reported to be expressed in b-cells (i.e., M1, M3, and
M4) [3, 5–8], selective M3 mAChR knockout in mice has
provided evidence that this receptor subtype is primarily
responsible for cholinergic actions in b-cells [3, 9].
The M3 mAChR preferentially couples to the Gaq/11-
phospholipase Cb (PLCb) signaling pathway. Activation of
PLCb generates inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG) through hydrolysis of phosphati-
dylinositol 4,5-bisphosphate (PIP2) [10]. IP3 activates IP3
receptors expressed on the endoplasmic reticulum (ER),
resulting in the release of Ca2? from the ER and an
increase in cytoplasmic Ca2? concentration ([Ca2?]i).
DAG is required for the activation of DAG-dependent
kinases, including both conventional and novel isoenzyme
subfamilies of PKC.
Stimulation of mAChRs in a variety of excitable and
non-excitable cells has been shown to activate multiple
signaling pathways, including the extracellular signal-reg-
ulated kinases, ERK1/2. For example, in the neuroblastoma
cell line SK-N-BE2(C), M3 mAChR activation stimulates
ERK1/2 phosphorylation via a PKCe-, Ras-, Raf- and
MEK-dependent mechanism that is independent of [Ca2?]i
[11, 12]. In contrast, the activation of ERK1/2 by M3
mAChR activation in human glial cells is dependent on
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Ca2? mobilization [13]. In rat islets of Langerhans, car-
bachol (carbamylcholine, a stable acetylcholine analog)
stimulates ERK1/2 phosphorylation [14], and ERK1/2
activation has been reported to stimulate b-cell prolifera-
tion and gene transcription, and to influence cell survival
and insulin secretion [15–18]. However, the signaling
pathway connecting mAChR to ERK1/2 activation in
b-cells is poorly understood. Therefore, the principal aim
of this study was to determine the signaling mecha-




Nifedipine and diazoxide were purchased from Calbio-
chem. All other chemicals (unless stated) were obtained
from Sigma.
Cell culture
MIN6 cells were used between passages 25 and 40
at *80% confluence and grown as described previously [19].
Cell treatments
Prior to treatment, the medium was removed and cells
washed twice with HEPES-balanced Krebs–Ringer bicar-
bonate (KRB) buffer (115 mM NaCl, 5 mM KCl, 10 mM
NaHCO3, 2.5 mM MgCl2, 2.5 mM CaCl2, 20 mM HEPES,
pH 7.4). The cells were then incubated for 1 h at 37C in
KRB buffer prior to treatments for the times indicated in
the figure legends. All inhibitors were added 30 min prior
to treatments. All treatments were stopped by the addition
of ice-cold lysis buffer (1% Triton-X100, 10 mM b-glyc-
erophosphate, 50 mM Tris–HCl, pH 7.5, 1 mM EDTA,
1 mM EGTA, 1 mM sodium orthovanadate, 1 mM ben-
zamidine HCl, 0.2 mM phenylmethylsulfonyl fluoride,
1 lg/mL each of leupeptin and pepstatin, 0.1%
b-mercaptoethanol, and 50 mM sodium fluoride). The
lysates were then centrifuged at 4C for 10 min at
16,0009g, supernatants kept, and total protein concentra-
tions determined by the Bradford assay (Bio-Rad). The
protein lysates were stored at -80C until further analysis.
Plasmid DNA constructs and transfections
Transfections of MIN6 cells were carried out only for
single-cell imaging studies. The DIER cameleon- [20],
eGFP-PHPLCd1- [21], and GFP-PKCe-containing plasmids
were provided by Prof. Roger Tsien (University of
California, USA), Prof. Stephen Ferguson (Roberts
Research Institute, University of Ontario, Canada) and
Prof. Tobias Meyer (Stanford University, USA), respec-
tively. DNA was transfected using LipofectAMINE2000
(Invitrogen) according to the manufacturer’s instructions.
Transfection efficiency was approximately 10–20% as
determined by GFP expression.
Adenoviral constructs and infection
AdRasN17 was a gift from Prof. B. Kahn and Dr.
C. Sutherland [22]. AdEmpty.eGFP has been described
previously [23]. MIN6 cells were infected with the viruses
for 48 h as previously described [23] prior to performing
the experiments. We routinely obtained 90–100% trans-
duction efficiency as assessed by GFP expression.
SDS–polyacrylamide gel electrophoresis (PAGE)
and immunoblotting
SDS–PAGE and Western blotting were performed as pre-
viously described [24]. Rabbit anti-phospho-ERK1/2 and
anti-ERK2 antibodies were purchased from Cell Signaling
Technology. Detection was by horseradish peroxidase-
linked anti-rabbit secondary antibodies and enhanced
chemiluminescence (Cheshire Biosciences).
Single-cell confocal Ca2? imaging
For Ca2? imaging, MIN6 cells were loaded for 30 min at
20C with 2 lM of Fluo-4-AM prepared in dye loading
buffer (KRB supplemented with 1 mg/mL BSA and 0.1%
Pluronic F-127). The cells were then washed in KRB and
incubated for a further 10 min in KRB to allow de-esteri-
fication of the indicator. Measurement of changes in fluo-
rescence, as an indicator of [Ca2?]i, was observed using a
PerkinElmer UltraVIEW confocal microscope. Fluo-4 was
excited using the 488-nm laser-line and 485-nm excitation
filter, and the emitted fluorescence was captured at wave-
lengths [520 nm, with images collected at approximately
2-s intervals. Raw fluorescence data were expressed as
F/F0. Data are reported as the mean SEM from at least
three individual experiments.
Population NOVOstar Ca2? imaging
Population-based Ca2? fluorescence measurements were
taken using a NOVOstar microplate reader (BMG Lab-
Technologies, Offenburg, Germany). MIN6 cells were
grown on a 96-well plate format, were washed twice with
KRB buffer and then loaded and equilibrated with 2 lM
Fluo-4-AM as described previously. Cells were excited at
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488 nm, with emission recorded at 520 nm every 0.5 s.
Raw fluorescence data were expressed as F/F0 (stimulated
fluorescence/basal fluorescence). Data are reported as the
average SEM from at least three individual experiments.
Single-cell confocal GFP imaging
Confocal imaging was performed using an Olympus FV300
scanning confocal microscope. Real-time images were
taken every second, and cells containing eGFP were
excited at 488 nm and emissions collected at 505–560 nm.
Application of agonists was via bath addition. Cytosolic
and membrane regions of interest were selected and aver-
age pixel intensity in that region was plotted against time.
Changes in fluorescence intensity were analyzed using
Fluoview Tiempo software (version 4.3). Fluorescent
intensity at a given time was divided by the initial fluo-
rescence within each region of interest and expressed as
F/F0 SEM.
FRET imaging
ER luminal Ca2? was imaged using the ER-localized
FRET-based D1ER cameleon [20]. Application of agonists
occurred via bath addition. Images were captured with the
209 objective of a Zeiss axiovert 200 M epifluorescence
microscope with a CCD camera controlled by Metafluor
software. Emission ratio imaging of the cameleon was
accomplished using a 436DF20 excitation filter, 450-nm
dichroic mirror, and two emission filters (475/40 for
enhanced CFP and 535/25 for citrine) controlled by a
Lambda 10-2 filter changer. Exposure times were typically
100–1,000 ms, and images were collected every 8–20 s.
Measurement of [3H]IPx
For the determination of 3H-labeled inositol mono-, bis-,
and trisphosphates ([3H]IPx), MIN6 cells were pre-labeled
with 2.5 lCi/mL myo-[3H]inositol (86 Ci/mmol) for 48 h
in 24-well multidishes. Medium was then removed, and the
cell monolayers washed and incubated for 30 min in 1 mL
of KRB in the absence or presence of 10 mM LiCl (see
‘‘Results’’ section). Carbachol was added as indicated and
incubations terminated by rapid aspiration and addition of
ice-cold 0.5 M trichloroacetic acid. Samples were neu-
tralized as described previously and the neutral extract
applied to Dowex (AG1-X8) formate columns, which was
then washed with 20 mL of water and 10 mL of 25 mM
ammonium formate. The [3H]IPx fraction was eluted with
10 mL of 1 M ammonium formate/0.1 M formic acid and
quantified by liquid scintillation spectrometry.
Measurement of [3H]phosphoinositides
[3H]Glycerophosphoinositolphosphates (GroPI, GroPI(4)P
and GroPI(4,5)P2), as indices of PI, PI(4)P, and PI(4,5)P2,
were prepared from cell monolayers based on previously
described methods [25]. After removal of the acidified
aqueous phase for the determination of [3H]IPx as descri-
bed above, lipids were extracted into 0.94 mL of acidified
chloroform/methanol (40:80:1 v/v, 10 M HCl). Chloroform
(0.31 mL) and 0.1 M HCl (0.56 mL) were then added to
induce phase partition. A sample of the lower phase (450
lL) was removed and dried in a stream of N2. Dried
samples were dissolved in 1 mL of chloroform and 0.2 mL
of methanol and hydrolyzed by the addition of 0.4 mL of
0.5 M NaOH in methanol/water (19:1, v/v). Samples were
vortex-mixed at regular intervals during a 20-min incuba-
tion at 25C. Chloroform (1 mL), methanol (0.6 mL), and
water (0.6 mL) were then added, and the samples were
mixed and centrifuged (3,000 9 g, 10 min). A 1-mL ali-
quot of the upper phase was neutralized using 1-mL bed
volume of Dowex-50 (H? form) columns that were washed
with 2 9 2 mL of water. The pooled eluate was brought to
pH 7 by the addition of NaHCO3 and applied to a Dowex
(AG1-X8) formate anion exchange column. The [3H]Gro-
PI, [3H]GroPI(4)P, and [3H]GroPI(4, 5)P2 were then eluted
as described elsewhere [25] and quantified by liquid scin-
tillation spectrometry.
Statistical analysis
Statistical differences between multiple groups were ana-
lyzed via either single-factor or two-way analysis of vari-
ance (ANOVA), followed by post hoc analysis as described
in figure legends. A statistical test was only carried out
when the experiments have at least n = 3. Statistical
analyses were performed in GraphPad Prism, and signifi-
cance was only confirmed when P \ 0.05 (*P \ 0.05;
**P \ 0.01; ***P \ 0.001).
Results
Characterization of carbachol-stimulated ERK1/2
phosphorylation in the pancreatic b-cell line MIN6
Carbachol addition caused a rapid, transient increase in the
phosphorylation of ERK1/2 (peaking at 2 min and rapidly
returning to basal levels within 10 min; Fig. 1a). The car-
bachol-stimulated phosphorylation of ERK1/2 at 2 min
was concentration dependent, yielding an EC50 value of
approx. 7 lM (Fig. 1b). Carbachol addition also stimulated
a rapid, concentration-dependent increase in [Ca2?]i (EC50
value approx. 0.9 lM) (Fig. 1c). To confirm that carbachol
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was mediating these actions via mAChR activation, MIN6
cells were treated with carbachol, or the mAChR-selective
agonist methacholine, in the absence and presence of the
mAChR antagonist atropine. Both the carbachol- and
methacholine-stimulated phosphorylations of ERK1/2 were
completely inhibited in the presence of atropine (Fig. 1d).
To examine the role of PLC in carbachol-stimulated
ERK1/2 phosphorylation, MIN6 cells were treated with
carbachol in the absence or presence of the PLC inhibitor
U71322. U71322 completely prevented carbachol-stimu-
lated ERK1/2 activation (Fig. 1e).
Carbachol-stimulated ERK1/2 activation is MEK
dependent and occurs via both Ras-dependent
and Ras-independent mechanisms
To investigate the role of Ras in carbachol-stimulated
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Fig. 1 Characterization of carbachol-stimulated increase in [Ca2?]i
and ERK1/2 activation. MIN6 cells pre-incubated for 1 h with KRB-
minus-glucose; a Carbachol (1 mM) for the times indicated; b carba-
chol at the concentrations indicated for 2 min. Proteins were
separated by SDS–PAGE and detected by Western blotting using
anti-phospho-ERK1/2 and anti-ERK2 antibodies. Data shown in
lower panel are means ? SEM (n = 3). **P \ 0.01, ***P \ 0.001;
one-way ANOVA followed by Dunnett’s range test comparing to no
carbachol addition. c Concentration–response curve for carbachol-
stimulated increases in [Ca2?]i determined in cell populations using a
NOVOstar plate reader. Data represent means SEM (n = 3) of the
peak change in fluorescence (DFU) correlating with peak increases in
[Ca2?]i. d Where indicated, cells were incubated with atropine (At,
10 lM) for 30 min prior to treatment with carbachol (Cch, 1 mM) or
methacholine (Mch, 1 mM) for 2 min. Proteins were separated by
SDS–PAGE and detected by Western blotting using anti-phospho-
ERK1/2 and anti-ERK2 antibodies. Data shown in lower panel are
means SEM (n = 3); ns no significance, ***P \ 0.001 by Dunnett’s
range test following one-way ANOVA comparing to no carbachol
addition. e MIN6 cells were pre-treated with U73122 (1 lM) for
30 min prior to treatment with carbachol (1 mM, 2 min). Proteins
were separated by SDS–PAGE and detected by Western blotting
using anti-phospho-ERK1/2 and anti-ERK2 antibodies. Lower panel
are means SEM (n = 3). Data were analyzed by a Student’s 2-tailed
t test; ***P \ 0.001. All immunoblots shown are representative of
three independent experiments
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recombinant adenovirus expressing dominant-negative Ras
(RasN17), and 48 h post-infection, cells were treated with
carbachol, EGF (which activate ERK1/2 in a Ras-depen-
dent manner) or GLP1 (which activates ERK1/2 in a
Ras-independent manner) [23]. As expected, RasN17
completely inhibited EGF-stimulated ERK1/2 phosphory-
lation and was without effect on the GLP1-stimulated
response (Fig. 2a). mAChR-mediated phosphorylation of
ERK1/2 was only partially inhibited, indicating that
carbachol can activate ERK1/2 by both Ras-dependent
and Ras-independent mechanisms (Fig. 2a). To determine
whether carbachol-stimulated ERK1/2 phosphorylation is
mediated by MEK, MIN6 cells were treated with carbachol
in the absence or presence of two structurally distinct MEK
inhibitors, PD184352 and U0126. Either inhibitor com-
pletely abolished carbachol-stimulated ERK1/2 phosphor-
ylation (Fig. 2b).
Carbachol-stimulated ERK1/2 phosphorylation
is independent of the activation of both conventional
and novel isoenzymes of PKC
Activation of PLCb by the M3 mAChR results in the
hydrolysis of PIP2 to generate IP3 and DAG [10, 26]. DAG
is required for the activation of DAG-dependent kinases,
including conventional and novel PKC isoenzymes [27],
which have been implicated in mAChR activation of
ERK1/2 [11, 12]. To confirm that carbachol activates the
PLC-DAG-PKC pathway in b-cells, MIN6 cells were
transfected with GFP-tagged PKCe (GFP-PKCe). Translo-
cation of this biosensor to the plasma membrane is indic-
ative of an increase in the concentration of DAG and the
activation of PKC. Both carbachol (Fig. 3a) and 12-o-tet-
radecanoylphorbol-13-acetate (TPA, a DAG-mimetic, used
as a positive control; Fig. 3b) treatment resulted in trans-
locations of GFP-PKCe from the cytosol to the plasma
membrane. To investigate the role of DAG-dependent
PKCs in carbachol-stimulated ERK1/2 activation, MIN6
cells were treated with carbachol or TPA in the absence or
presence of the PKC inhibitors, bisindolylmaleimide I
(BIM I), Ro 32-0432 and Go¨6976, which inhibit both
conventional and novel PKCs [28–30]. In addition, MIN6
cells were stimulated with TPA overnight to down-regulate
the expression of all DAG-dependent PKCs [24, 27] before
treatment with carbachol or TPA. None of the PKC
inhibitors, or chronic TPA pre-treatment, significantly
inhibited carbachol-induced ERK1/2 activation (Fig. 3c),
whereas each manipulation substantially inhibited acute
TPA-stimulated ERK1/2 activation (Fig. 3d).
Increases in [Ca2?]i are essential
for carbachol-stimulated ERK1/2 phosphorylation
Carbachol stimulated concentration-dependent increases in
[Ca2?]i that paralleled ERK1/2 activation (Fig. 1b, c). To
determine whether this increase in [Ca2?]i was essential for
ERK1/2 activation, MIN6 cells were loaded with the Ca2?
chelator BAPTA-AM prior to carbachol addition. BAPTA-
AM substantially attenuated carbachol-induced ERK1/2
activation (Fig. 4a) and abolished the agonist-stimulated
change in [Ca2?]i (Fig. 4b). Incubation of MIN6 cells in
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Fig. 2 Role of Ras and MEK in carbachol-stimulated ERK1/2
activation. a MIN6 cells were infected with a control adenovirus
(AdEmpty.eGFP) or with an adenovirus engineered for expression of
RasN17 (AdRasN17). After 48 h, cells were pre-incubated for 1 h
with KRB-minus-glucose before treatment with carbachol (1 mM,
2 min), EGF (20 ng/ml, 5 min) or GLP-1 (10 nM) plus 16.7 mM
glucose for 10 min. b MIN6 cells were pre-incubated for 1 h in KRB
and where indicated PD098059 (PD, 1 lM) or U0126 (20 lM) was
added for the last 30 min before addition of carbachol (1 mM, 2 min).
Proteins were separated by SDS–PAGE and detected by Western
blotting using anti-phospho-ERK1/2 and anti-ERK2 antibodies.
Below each representative blot is a graph showing densitometric
quantification of ERK1/2 phosphorylation. Data are presented as
means SEM (n = 3); ***P \ 0.001 by Dunnett’s range test following
one-way ANOVA compared to the carbachol response
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nM abolishing the transmembrane [Ca2?] gradient) inhib-
ited both carbachol-stimulated ERK1/2 activation (Fig. 4c)
and the increase in [Ca2?]i (Fig. 4d). Therefore, carbachol-
stimulated ERK1/2 activation is dependent on an increase
in [Ca2?]i, which is primarily dependent on Ca
2? influx.
Investigating the mechanism of carbachol-induced
increases in [Ca2?]i and ERK1/2 phosphorylation
To investigate how carbachol elicits an increase in [Ca2?]i
and to gain an insight into how this may lead to ERK1/2
activation, MIN6 cells were pre-incubated with nifedipine
(10 lM; an L-type voltage-operated Ca2? channel (VOC)
blocker), diazoxide (250 lM; a KATP channel activator),
2-APB (10 lM; a store-operated Ca2? channel (SOC) and
IP3 receptor inhibitor), xestospongin C (10 lM; an IP3
receptor antagonist), or thapsigargin (1 lM; a SERCA
pump inhibitor, which leads to ER Ca2? store depletion)
before carbachol addition.
Pre-treatment of MIN6 cells with nifedipine or diazox-
ide effectively abolished carbachol-induced ERK1/2 acti-
vation and peak [Ca2?]i (Fig. 5a, b). These data indicate
that the activation of the L-type VOCs is required for
carbachol-induced Ca2? influx and ERK1/2 activation,
while the diazoxide effect suggests a potential involvement
of KATP. The IP3 receptor antagonists, xestospongin C and
2-APB, also significantly attenuated carbachol-stimulated
ERK1/2 activation and peak [Ca2?]i. However, xesto-
spongin C was unable to block completely increases in
[Ca2?]i (Fig. 5a, b). To determine the effectiveness of
xestospongin C and 2-APB in inhibiting IP3 receptor-


















































pre-incubated for 1 h in
KRB-minus-glucose prior to
treatment with a carbachol
(1 mM) or b TPA (1 lM).
Fluorescence intensity in the
(i) cytoplasm or (ii) at the




expressed relative to initial
fluorescence (F/F0). c, d MIN6
cells pre-treated in the absence
or presence of TPA (1 lM) for
16 h (TPA o/n) were pre-
incubated for 1 h in KRB-
minus-glucose prior to
treatment with c carbachol
(1 mM, 2 min) or d TPA
(1 lM, 60 min) in the absence
or presence of
bisindolylmaleimide
I (BIM, 1 lM), Ro 32-0432
(Ro32, 1 lM), or Go¨6976
(Go69, 1 lM). Proteins were
separated by SDS–PAGE and
detected by Western blotting
using anti-phospho-ERK1/2 and
anti-ERK2 antibodies.
Representative blots are shown
above with mean data
densitometry below in panels
c and d. Data are shown as
means ? SEM (n = 3);
***P \ 0.001 by Dunnett’s
range test following one-way
ANOVA compared to carbachol
(panel c) or TPA (panel d)
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with these inhibitors and the [Ca2?] within the endoplasmic
reticulum lumen ([Ca2?]ER) measured using the D1ER
FRET sensor [20]. Stimulation of MIN6 cells with carba-
chol caused a decrease in [Ca2?]ER (Fig. 5c), which was
prevented by xestospongin C (Fig. 5c). In contrast, 2-APB
had no significant effect on carbachol-induced decreases in
[Ca2?]ER (Fig. 5c), demonstrating that it is not effective in
MIN6 cells as an IP3 receptor antagonist. Therefore, the
inhibitory effect of 2-APB on carbachol-induced ERK1/2
activation and Ca2? mobilization is likely to be occurring
through an action at SOCs, another known target of this
inhibitor [31].
Although we have demonstrated that IP3 receptor
antagonism prevents carbachol-induced ERK1/2 activation
in MIN6 cells, pre-treatment of MIN6 cells with thapsi-
gargin failed to inhibit carbachol-stimulated ERK1/2
activation (Fig. 5d), yet significantly lowered the peak
[Ca2?]i response (Fig. 5b). To determine whether thapsi-
gargin is emptying ER stores of Ca2?, MIN6 cells were
pre-incubated with 1 lM thapsigargin for 10 min and
[Ca2?]ER measured (Fig. 5f). This resulted in a decrease in
[Ca2?]ER. Yet, the subsequent application of carbachol did
not lead to a further decrease in [Ca2?]ER (Fig. 5f), indi-
cating that thapsigargin had indeed depleted the ER of
Ca2?. So why is pre-treatment with thapsigargin unable to
inhibit carbachol-stimulated ERK1/2 activation? One
explanation for this apparent paradox is that thapsigargin is
increasing the [Ca2?]i sufficiently to compensate for the
loss of IP3-mediated Ca
2? efflux from the ER. To inves-
tigate this possibility, changes in [Ca2?]i was measured
during the thapsigargin pre-treatment and on subsequent
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Fig. 4 Ca2? influx across the plasma membrane is required for
carbachol-stimulated ERK1/2 activation. a MIN6 cells were pre-
incubated for 30 min in KRB-minus-glucose and, where indicated,
loaded with BAPTA-AM (100 lM, BAPTA) for 30 min. Cells were
then treated with carbachol (1 mM, 2 min). Proteins were separated
by SDS–PAGE and detected by Western blotting using anti-phospho-
ERK1/2 and anti-ERK2 antibodies. A representative blot is shown
above with mean data densitometry below. Data are shown as means
SEM (n = 3); ***P \ 0.001 by Dunnett’s range test following one-
way ANOVA compared to carbachol. b Cells were loaded with Fluo-
4-AM (2 lM) at the same time as BAPTA-AM and [Ca2?]i measured
using single-cell confocal Ca2? imaging following carbachol (1 mM)
addition. Data represent means SEM for the increase in [Ca2?]i levels
(n [ 30). c MIN6 cells were pre-incubated for 30 min in KRB-minus-
glucose and, where indicated, incubated in EGTA-buffered KRB for
the last 10 min. The Ca2? concentration in the KRB was reduced
to B 100 nM by EGTA-buffering and confirmed using Fura-2 free
acid and standard fluorimetry. Carbachol (1 mM) was added to the
KRB for 2 min. Proteins were separated by SDS–PAGE and detected
by Western blotting using anti-phospho-ERK1/2 and anti-ERK2
antibodies. A representative blot is shown above with densitometry
below. Data are means SEM (n [ 3); ***P \ 0.001 by Dunnett’s
range test following one-way ANOVA compared to carbachol.
d Changes in [Ca2?]i were assessed by single-cell confocal Ca
2?
imaging reproducing the experimental conditions used in panel c
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pre-incubation caused a significant increase in [Ca2?]i
levels over the 10-min period (Fig. 5g), yet carbachol-
stimulated increases in [Ca2?]i were unaffected. Therefore,
it is possible that the increase in [Ca2?]i caused by
thapsigargin pre-treatment is sufficient to recapitulate IP3
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treatment and thus explain why thapsigargin treatment has
no significant effect on carbachol-stimulated increases in
[Ca2?]i or ERK1/2 activation.
It has been reported that ACh depolarizes the b-cell
by increasing its membrane permeability to Na? [32].
However, the replacement of extracellular Na? with N-
methyl-glucamine had no significant effect on carbachol-
stimulated ERK activation (Fig. 5e).
Taken together, these data provide evidence that car-
bachol-evoked increases in intracellular Ca2? and ERK1/2
activation are mediated by (1) the release of Ca2? from ER
stores via IP3 receptor activation; (2) the influx of extra-
cellular Ca2? through activation of SOCs and; (3) depo-
larization and activation of L-type VOCs, likely through
KATP channel closure.
Characterization of changes in membrane
phosphoinositides in response to M3 mAChR
stimulation
Changes in the ATP/ADP ratio and phosphatidylino-
sitol 4,5-bisphosphate (PIP2) concentration are known to
regulate KATP channel activity in pancreatic b-cells [33–
35]. However, the ATP/ADP ratio is unlikely to change on
mAChR activation alone in the absence of glucose.
Therefore, we hypothesized that carbachol may be stimu-
lating KATP channel closure through agonist-stimulated
decreases in PIP2 concentration at the plasma membrane.
The membrane association of the PH-domain of PLCd1
fused to eGFP (eGFP-PHPLCd1) has been used as a bio-
sensor to assess inositol 1,4,5-trisphosphate (IP3) genera-
tion and changes in PIP2 concentration at the single-cell
level [36–41]. Therefore, to indirectly measure changes in
[IP3] and/or [PIP2], MIN6 cells were transfected with
eGFP-PHPLCd1and changes in fluorescence determined in
response to carbachol. In unstimulated MIN6 cells, the
eGFP-PHPLCd1 is localized at the plasma membrane. On
carbachol stimulation, eGFP-PHPLCd1 translocated to the
cytosol (Fig. 6a) with a corresponding reduction in fluo-
rescence at the plasma membrane (Fig. 6a), indicative of
an increase in [IP3] and/or a reduction in plasma membrane
[PIP2]. To extend these observations, we determined bio-
chemically whether carbachol stimulation of MIN6 cells
caused changes in phosphatidylinositol (PI), phosphati-
dylinositol 4-phosphate (PIP), and PIP2 concentration at
the plasma membrane in [3H]inositol-labeled MIN6 cells.
PIP and PIP2 were found to make up only a small pro-
portion (1.7 and 2.3%, respectively) of the total phospho-
inositide pool. Stimulation with carbachol for 60 s
decreased PIP2 to 85 ± 2% and PIP to 73 ± 3% of their
respective initial values. These changes were maintained
throughout the time course of agonist stimulation (PIP2,
89 ± 1% and PIP, 68 ± 5% of pre-stimulation values at
15 min post-carbachol addition; Fig. 6bii). The greater
decrease in PIP compared to PIP2 suggests that the latter
polyphosphoinositide is relatively protected from agonist-
induced changes by greater changes in its immediate
precursor.
Discussion
The present study provides evidence that carbachol,
through the activation of a Gq-coupled mAChR, results in a
transient MEK-dependent phosphorylation of ERK1/2 in
the pancreatic b-cell line MIN6. We show that carbachol-
induced activation of ERK is independent of both the
activation of novel and classical PKCs, but is dependent on
an increase in [Ca2?]i. We also show that this increase in
[Ca2?]i is likely mediated by both an IP3-dependent efflux
of Ca2? from the endoplasmic reticulum and the influx of
extracellular Ca2? through both store-operated (SOC) and
L-type voltage-operated (VOC) Ca2? channels (see Fig. 7).
mAChR activation in MIN6 cells leads to an IP3
receptor-dependent efflux of Ca2? from the ER. This is
Fig. 5 Multiple Ca2? sources are required for carbachol-stimulated
ERK1/2 activation. a MIN6 cells were pre-incubated for 1 h with
KRB-minus-glucose in the absence or presence of 2APB (10 lM) for
30 min, or nifedipine (10 lM), xestospongin C (10 lM) or diazoxide
(250 lM) for 10 min prior to carbachol (1 mM, 2 min) addition.
Proteins were separated by SDS–PAGE and detected by Western
blotting using anti-phospho-ERK1/2 and anti-ERK2 antibodies. A
representative blot is shown above with mean data densitometry
below. Data are shown as means SEM (n = 3); *P \ 0.05;
***P \ 0.001 by Dunnett’s range test following one-way ANOVA
compared to carbachol addition. b [Ca2?]i was monitored in popu-
lations of MIN6 cells pre-treated as in a by NOVOstar platereader.
Data are shown as means SEM (n = 3); *P \ 0.05; ***P \ 0.001 by
Dunnett’s range test following one-way ANOVA compared to
carbachol addition. c MIN6 cells transfected with the cameleon
D1ER construct were pre-incubated for 1 h in KRB-minus-glucose.
Cells were then incubated in the absence or presence of 2ABP
(10 lM) or xestospongin C (10 lM) for 10 min before the addition of
carbachol (Cch, 1 mM). Data shown represent peak FRET changes
after agonist addition. d MIN6 cells were treated as in a, but in the
absence or presence of thapsigargin (1 lM) pre-addition for 10 min. A
representative blot is shown above with mean data densitometry
below. e MIN6 cells were maintained in KRB in which Na? was
replaced by methylglucamine for 15 min before stimulation with
either glucose (20 mM) or carbachol (1 mM). Data are shown as
means SEM (n = 3); *P \ 0.05; ***P \ 0.001 by Dunnett’s range
test following one-way ANOVA compared to carbachol. f MIN6 cells
transfected with cameleon D1ER were pre-incubated for 1 h in KRB-
minus-glucose prior to recording. All recordings show 1 min of basal
KRB perfusion before either no pre-treatment or thapsigargin (1 lM)
addition for 10 min followed by the addition of carbachol (1 mM) for
5 min. Data shown represent mean changes in FRET for n C 30 cells.
g MIN6 cells were pre-incubated in KRB-minus-glucose and then
treated with carbachol (1 mM, black line) or thapsigargin (1 lM, gray
line) for 10 min followed by the addition of carbachol (1 mM).
Fluorescence was measured as an indicator of [Ca2?]i by NOVOstar
platereader for 10 s before initial Cch/thapsigargin pre-treatments
b
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required for, but is not sufficient to cause, the activation of
ERK1/2, as carbachol-stimulated ERK1/2 activation also
requires the influx of extracellular Ca2?. This influx of
Ca2? is likely via SOCs and L-type VOCs as the increase
in [Ca2?]i, and indeed ERK1/2 phosphorylation, is blocked
by either 2-APB (an inhibitor of SOCs, which does not
inhibit IP3 receptors in this cell type) or nifedipine (an
L-type VOC antagonist). As depolarization is a prerequisite
for L-type VOC activation and carbachol-stimulated
increases in [Ca2?]i are nifedipine-sensitive, carbachol
must induce membrane depolarization. This is likely
mediated by multiple mechanisms, including KATP channel
Fig. 6 Changes in phosphoinositide turnover in MIN6 cells in
response to carbachol. a MIN6 cells were transfected with a plasmid
encoding eGFP-PHPLCd1. Cells were then pre-treated for 1 h with
KRB-minus-glucose and treated with carbachol (1 mM). Changes in
fluorescence intensity at the plasma membrane (i) or in the cytoplasm
(ii) were determined by confocal microscopy. Fluorescence intensity
was referenced to the initial fluorescence (F/F0). The area under the
baseline for membrane fluorescence or over the baseline for
cytoplasmic fluorescence was calculated and compared between
control and carbachol-stimulated cells. Data are presented as means
SEM (n [ 30). b MIN6 cells were incubated with [3H]inositol for
48 h. Cells were pre-incubated for 1 h with KRB-minus-glucose and,
where indicated, LiCl (10 mM) was added for the final 30 min. Cells
were challenged with carbachol (1 mM) for the times indicated and
[3H]IPx and [
3H]PtdIns(Px) fractions recovered and analyzed as
described in the ‘‘Methods’’ section. Time-dependent effects of
carbachol stimulation on (i) [3H]IPx accumulations in the absence and
presence of LiCl and (ii) [3H]PtdIns, [3H]PtdInsP and [3H]PtdInsP2.
Data are shown as means ? SEM for 3 independent experiments
performed in duplicate
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closure, Ca2? release from the ER via IP3 receptors, and
Ca2? influx via SOCS, as both carbachol-stimulated ERK1/
2 phosphorylation and increased [Ca2?]i are significantly
inhibited by diazoxide, 2APB and xestospongin C. These
results are in general agreement with, and extend, previous
observations showing that mAChR activation, in the
absence of glucose, stimulates increases in [Ca2?]i via
VOCs in both primary mouse b-cells and rat islets [32, 34].
The molecular mechanism of KATP channels closure in
response to carbachol treatment is unknown. However, one
possibility is that carbachol activation of PLCb could lead
to a decrease in plasma membrane PIP2 levels, which is
known to regulate KATP channel activity in pancreatic b-
cells [33–35]. mAChR stimulation clearly causes increased
phosphoinositide turnover as indicated by the plasma
membrane-to-cytoplasm translocation of eGFP-PH and
increased accumulation of [3H]IPx in MIN6 cells. Yet, we
could only detect relatively small decreases in PIP2, and it
is unclear whether this would be sufficient to significantly
alter KATP channel activity. Changes in PIP levels were
relatively greater, indicating that PIP2 levels may be pro-
tected at the expense of PIP during mAChR stimulation in
MIN6 cells. In another cell type, the human neuroblastoma
SH-SY5Y, which endogenously expresses M3 mAChRs,
agonist addition stimulates much greater changes in PIP/
PIP2 levels (70–80% decreases) [25]. Nevertheless, it must
be acknowledged that the methods used here are measuring
global changes in PIP2, and it is possible that within the
immediate vicinity of the activated mAChR, the changes in
polyphosphoinositide levels may be greater. At present,
there is no evidence that mAChRs and the signal trans-
duction machinery necessary to modulate KATP are brought
together within a microenvironment such as a lipid raft, but
intriguingly the disruption of b-cell lipid rafts modifies
Kv2.1 channel gating [42]. Therefore, it remains a possi-
bility that changes in PIP2 and/or PIP concentration affect
ion channel activity, and hence the activation of ERK1/2.
SOC channel activation is dependent on IP3-mediated
Ca2? release from the ER [43–45]. Therefore, mAChR
activation of SOCs in MIN6 cells is also likely to be
mediated by IP3 receptor activation. mAChR activation has
been shown to stimulate ‘‘capacitative’’ (ER store-deple-
tion-driven) Ca2? entry in HIT-T15 cells and mouse pan-
creatic b-cells through the emptying of intracellular Ca2?
stores [46]. Capacitative Ca2? entry has been reported to be
relatively small in pancreatic b-cells, and, unlike other
systems, it is not dependent on the energy status of the cell
or PKC activation and is unaffected by protein phosphatase
or tyrosine kinase inhibition [47]. However, capacitative
Ca2? entry does affect membrane potential and could
therefore influence the activity of the VOCs [48–50].
Our group had previously reported that GLP-1 stimu-
lates ERK activation in MIN6 cells via Ca2? influx through
L-type VOCs and that this is mediated by a Ras-indepen-
dent mechanism [23]. Interestingly, carbachol-stimulated
ERK activation also requires the activation of L-type
VOCs and is in part independent of Ras activation.
Therefore, it is likely that this Ras-independent but Ca2?-
dependent ERK1/2 activation is mediated by L-type VOC
signaling to ERK [23]. A proportion of carbachol-stimu-
lated ERK1/2 activation is both Ras- and Ca2?-dependent:
this could be occurring through the activation of Ca2?-
dependent guanine nucleotide exchange factors (GEFs) for
Ras such as Ras-GRP/Ras-GRF [51, 52].
The role of mAChR activation of ERK1/2 in pancreatic
b-cells is currently unknown. However, the activation of
ERK1/2 in b-cells, elicited by various nutrients and hor-
mones, has been shown to be important in the stimulation
of pancreatic b-cell proliferation, differentiation, survival,
and gene transcription [15, 16, 53]. Intriguingly, M1 and
M3 mAChR expression has been reported to be up-regu-
lated and to stimulate islet cell proliferation during
pancreatic regeneration [54], indicating that mAChR
activation, possibly through the activation of ERK1/2, may
play a positive role in b-cell proliferation. Moreover, in
MIN6 cells, glucose-stimulated ERK1/2 activation has
been shown to play an important role in enhancing insulin
exocytosis, via the phosphorylation of synapsin I [18].
Therefore, it is also possible that mAChR activation of
ERK plays a role in receptor-mediated potentiation of
glucose-stimulated insulin secretion.
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Fig. 7 Schematic synopsis of the mechanisms of carbachol-stimu-
lated ERK1/2 activation in MIN6 cells. (1) Agonist binding to the
mAchR activates PLC resulting in phosphoinositide hydrolysis and
the production of IP3; (2) activation of IP3Rs in the ER increases
cytoplasmic [Ca2?]; (3) plasma membrane store-operated channels
mediate Ca2? entry; (4) KATP channels are inactivated; (5) steps 2–4
converge resulting in depolarization and Ca2? entry through L-type
VGCCs. The increase in [Ca2?]i results in ERK1/2 activation
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